Correspondingly, the resistance scores progressively increased from stages I to IV of RCC tumor progression, suggesting that the ability to evade CD40L-CD40–mediated cytotoxicity is a critical factor for tumor progression and cancer immune evasion (fig. This evidence concerns the gene CD40 and renal cell carcinoma.